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The Neurexin 3 gene (NRXN3) has been associated
with dependence on various addictive substances, as
well as with the degree of smoking in schizophrenic
patients and impulsivity among tobacco abusers. To
further evaluate the role of NRXN3 in nicotine addiction,
we analyzed single nucleotide polymorphisms (SNPs)
and a copy number variant (CNV) within the NRXN3
genomic region. An initial study was carried out on
157 smokers and 595 controls, all of Spanish Caucasian
origin. Nicotine dependence was assessed using the
Fagerstro¨m index and the number of cigarettes smoked
per day. The 45 NRXN3 SNPs genotyped included
all the SNPs previously associated with disease, and
a previously described deletion within NRXN3. This
analysis was replicated in 276 additional independent
smokers and 568 controls. Case–control association
analyses were performed at the allele, genotype and
haplotype levels. Allelic and genotypic association tests
showed that three NRXN3 SNPs were associated with
a lower risk of being a smoker. The haplotype analysis
showed that one block of 16 Kb, consisting of two of
the significant SNPs (rs221473 and rs221497), was also
associated with lower risk of being a smoker in both
the discovery and the replication cohorts, reaching a
higher level of significance when the whole sample
was considered [odds ratio = 0.57 (0.42–0.77), permuted
P = 0.0075]. By contrast, the NRXN3 CNV was not
associated with smoking behavior. Taken together, our
results confirm a role for NRXN3 in susceptibility to
smoking behavior, and strongly implicate this gene in
genetic vulnerability to addictive behaviors.
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According to the 2011 World Health Organization report on
the global tobacco epidemic, tobacco kills nearly 6 million
people each year, causing hundreds of billions of dollars of
economic damage worldwide (WHO 2011). In fact, smoking
is the single greatest contributor to preventable ill health and
premature death (reviewed in Bierut 2011). The development
of nicotine addiction is influenced by environmental and
genetic factors, and while environmental factors have a
stronger influence on initiation, genetic factors play a more
significant role in the transition from regular use to addiction
(Bierut 2011; Vink et al. 2005).
A genetic component in the development of nicotine
addiction has been showed in twin and family studies,
showing an estimated heritability of 30–72% (Agrawal et al.
2008). Twin studies also showed a hereditary component
for a range of diverse smoking-related phenotypes, including
age at initiation, intensity and cessation (Heath et al. 2002).
Similarly, familial studies showed that siblings of habitual-
smoking probands are at greater risk of becoming habitual
smokers (Bierut et al. 1998).
At the molecular level, efforts to untangle the genetic
component of nicotine addiction have focused on both the
study of candidate genes and on hypothesis-free whole
genome analyses. To date, the most robust genetic finding
is the link between nicotine addiction and two gene clusters
of nicotine receptors: α3, α5 and β4 (CHRNA3, CHRNA5 and
CHRNB4) on chromosome 15; and α6 and β3 (CHRNA6
and CHRNB3) on chromosome 8 (Tagconsortium 2010;
Thorgeirsson et al. 2008). In spite of the reported strong
associations, the contribution of nicotinic receptor genes
to susceptibility to nicotine addiction only partially explains
the heritability of this condition, suggesting that other
genes contribute in an additive or epistatic manner to the
development of nicotine addiction.
Nicotine dependence has also been associated with
the Neurexin genes (Bierut et al. 2007; Nussbaum et al.
2008). Neurexins are presynaptic cell adhesion proteins
that are essential for the development and function of
GABAergic and glutamatergic synapses (Craig et al. 2006;
Sudhof 2008). These synapses participate in key circuits
influencing addictive behaviors (Lein et al. 2007; Ullrich
et al. 1995). Two members of the neurexin gene family
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have been associated with nicotine dependence, Neurexin 1
and Neurexin 3 (Bierut et al. 2007; Nussbaum et al. 2008).
Moreover, Neurexin 3 has also been associated with the
degree of smoking in schizophrenic patients (Novak et al.
2009), impulsivity and substance abuse (Stoltenberg et al.
2011), illegal substance abuse (Lachman et al. 2007) and
alcohol dependence (Hishimoto et al. 2007).
In addition to single nucleotide polymorphisms (SNPs),
structural variants involving neurexin genes have been
described in autism spectrum disorders (Ching et al.
2010; Gauthier et al. 2011; Kim et al. 2008; Vaags et al.
2012; Wisniowiecka-Kowalnik et al. 2010) and schizophrenia
patients (Kirov et al. 2008). These copy number variants
(CNVs) are rare, large rearrangements. A common CNV
in Neurexin 3 (NRXN3) has also been described (Conrad
et al. 2010). The latter CNV, termed NRXN3_del henceforth,
involves a common insertion/deletion polymorphism span-
ning 8.9 kb of the second intron of the NRXN3 β isoform, and
its association with disease/psychiatric phenotypes has not
been investigated. As tobacco addiction is a common mild
phenotype, NRXN3_del may be involved in susceptibility to
smoking behavior.
In the present study we investigated the role of NRXN3 in
nicotine addiction. We performed a comprehensive genetic
study in Spanish smokers and control subjects, which
included analysis of tagSNPs and candidate SNPs, and the
common CNV located within the NRXN3 gene.
Materials and methods
Samples
All participants in the smoking group were individuals interested
in receiving treatment to give up smoking. The original cohort
(TAB_Discovery) included 157 smokers recruited and evaluated
at the Tobacco Unit of the Addictive Behavior Unit at the
Hospital Universitari Vall d’ Hebron (Barcelona, Catalonia, Spain).
These subjects were evaluated with the Addiction Research Unit
questionnaire (ARU) (West & Russell 1985), the Beck Depression
Inventory (BDI) (Beck et al. 1961) and the State-Trait Anxiety
Inventory (STAI) (Spielberger et al., 1970). Subjects smoking regularly
that requested for treatment to quit smoking were considered as
smokers. The replication sample (TAB_replication) consisted of 276
smokers, recruited at different primary care centers in Catalonia,
Spain (ClinicalTrials.gov identifier: NCT00125905). These subjects
were evaluated with the Richmond test, to assess their motivation
to quit smoking. In these sample sets, subjects smoking regularly
and willing to quit smoking were considered as smokers. Nicotine
dependence was assessed in both samples using the Fagerstro¨m
index (Heatherton et al. 1991) and through the number of cigarettes
smoked per day.
The control sample consisted of 1163 healthy blood donors
recruited from the Blood bank (Banc de Sang i de Teixits) at
the Hospital Universitari Vall d’Hebron. Blood donors were asked
to fill in a questionnaire including the question ‘have you ever
smoked’; subjects providing a negative answer were considered
non-smokers. This control sample was further divided into two
random cohorts using the ‘Research Randomizer’ v.3.0 software
(http://www.randomizer.org/): CVH1 (n = 595) and CVH2 (n = 568).
CVH1 and CVH2 were used as controls for the discovery and
replication cohorts, respectively. No significant differences in sex
or age were detected between the groups, and the demographic
and clinical attributes associated with the samples are summarized
in Table 1.
All participants, both cases and controls, were of Spanish
Caucasian origin and they provided informed consent before
enrollment. The project was approved by the ethics committees
at all the participating recruitment centers.
Genotyping of NRXN3 variants
We selected 45 SNPs within the genomic region of NRXN3 using
the Haploview software (Barrett et al. 2005). These SNPs capture
42% of alleles in NRXN3α (1460 kb) and 66% in NRXN3β at r2 ≥
0.8, based on the CEU HapMap genotyped SNPs (version 2, release
21). In the selection process, potential functional variants, variants
located near splice sites and SNPs previously associated with dis-
ease were included as TagSNPs (Heard-Costa et al. 2009; Hishimoto
et al. 2007; Novak et al. 2009). A total of 45 SNPs (41 TagSNPs and
4 singleton SNPs) and 1320 samples (CVH1, CVH2 and TAB_Discov-
ery) were genotyped (Table 2) using VeraCode technology (Illumina,
Inc., San Diego, CA, USA) at the CeGen genotyping facility (Cen-
tro Nacional de Genotipado, Genoma Espan˜a, Barcelona), following
the manufacturer’s instructions. The assays developed for the Ver-
aCode beads were analyzed using Illumina’s BeadXpress Reader
System and the data analyzed using BeadStudio v.2.0 software
(Illumina, Inc., San Diego, CA, USA). As a quality control, 5% of
the genotyped samples were duplicated, and no-template controls




We also explored the possible involvement of a previously
described NRXN3 CNV in susceptibility to smoking behavior.
This CNV, NRXN3_del, consists of a common insertion/deletion
polymorphism spanning 8.9 kb of the second intron of the NRXN3 β
isoform (Conrad et al. 2010). To genotype this structural variant, we
included two SNPs located within the deleted region in the Veracode
assay (rs12894142 and rs12100748), and we designed a third SNP
assay (NRXN3del) with each of its extension probes flanking the
breakpoints of the CNV. A combination of the results for these
SNPs was used to assess the genotype. In addition, NRXN3_del was
genotyped by multiplex polymerase chain reactions (PCRs) with 5′







(N = 595) (N = 568) (N = 157) (N = ‘276)
Gender, n (%)
Male 216 (36.6) 180 (31.7) 82 (53.6) 118 (43.2)
Female 375 (63.4) 388 (68.3) 69 (46.4) 155 (56.8)
Mean age, yrs (±SD) 53.8 (16.8) 54.1 (17.5) 46.6 (7.7) 45.5 (13.5)
Cigarettes/day (±SD) – – 21.9 (9.9) 19.8 (11.4)
Fagerstro¨m score (±SD) – – 5.12 (2.42) 4.16 (2.58)
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Table 2: SNPs tested for association
Name Position Hwpval %Geno MAF Alleles P value∗
rs1004212† 78250978 1 99.6 0.134 G:A 0.1609
rs31431 78510788 1 99.9 0.124 C:A 0.4279
rs17108457 78520530 1 100 0.111 A:T 0.2536
rs2202167 78569377 0.6121 99.6 0.385 C:A 0.5141
rs2202175 78625403 0.2421 99.7 0.394 A:C 0.9386
rs12323794 78631351 0.2865 100 0.365 G:A 0.5657
rs6574495 78669026 1 100 0.396 G:A 0.6821
rs11627269 78784324 1 100 0.332 G:A 0.6109
rs4603484 78925469 0.9725 100 0.432 A:C 0.3402
rs2196443 78946968 0.1608 100 0.194 A:C 0.0369
rs10146997† 79014914 0.047 100 0.179 A:G 0.4977
rs11848580 79038540 0.0332 99.9 0.392 A:G 0.0368
rs1424850 79067756 0.28 100 0.285 T:A 0.0002
rs221415 79115621 0.829 100 0.183 A:G 0.1393
rs7153625 79119014 1 99.7 0.172 G:A 0.4427
rs8022725 79129222 0.8011 100 0.359 G:C 0.2103
rs2543576 79141981 0.433 99.9 0.446 G:A 0.0143
rs221497 79158232 0.3867 100 0.112 G:A 0.0020
rs221473 79174368 1 100 0.187 A:T 0.0009
NRXN3del 79176041 1 65.6 0 G:G NA
rs12894142 79179213 1.11E-07 83.4 0.027 A:G NA
rs12100748 79183747 5.00E-04 83.8 0.007 G:A NA
rs221449 79193929 1 99.5 0.258 G:A 0.1448
rs10130593 79211814 1 100 0.321 C:G 0.4242
rs1030127 79231192 0.8693 100 0.123 A:G 0.5384
rs178377 79247778 0.6315 100 0.147 A:G 0.3535
rs8021767 79263758 1 99.9 0.198 G:A 0.1039
rs5014481 79282614 0.2073 100 0.429 C:A 0.7918
rs8018724 79318557 0.4432 100 0.368 C:A 0.3199
rs2215840† 79339820 0.7087 100 0.371 A:G 0.9289
rs10145867 79339926 0.7731 100 0.083 G:A 0.2061
rs932265 79360177 0.4085 100 0.159 G:A 0.1521
rs1159039 79361345 0.2736 100 0.344 A:G 0.8745
rs760288† 79376682 0.5889 100 0.336 A:G 0.6339
rs2293839 79387212 0.2407 100 0.304 G:A 0.9259
rs8019381† 79390335 0.3627 100 0.162 G:A 0.4028
rs994010 79419355 0.6763 100 0.235 A:G 0.5751
rs9323679 79421543 0.3453 100 0.145 A:G 0.6752
Markers included in the NRXN3-del genotyping appear in bold.
∗Genotypic association under the log-additive model corrected
by sex and age.
†SNPs analyzed in substance-abuse-related papers.
FAM modification, followed by capillary electrophoresis in a 3730XL
automatic sequencer and analysis with the Gene Mapper package
(Applied Biosystems, Foster City, CA, USA). In each experiment,
we included both negative and positive controls, consisting of three
Hapmap samples with validated genotypes for this CNV (Conrad et al.
2010): NA06991 (homozygous deleted), NA010831 (heterozygous)
and NA06994 (homozygous non-deleted). The observed concordance
between the two assays was 100%.
SNPs with a significant association in the discovery samples
(rs1424850, rs221473 and rs221497) were subsequently genotyped
using the KBiosciences PCR SNP genotyping system (KASPar®,
Kbioscience, Hoddesdon, Herts, UK), which uses a competitive allele-
specific PCR, following the manufacturer’s instructions. Genotyping
of the independent smoker cohort (276 additional smokers) was
performed at the CeGen genotyping facilities, in the CNIO Node
(Centro Nacional de Genotipado, Genoma Espan˜a). As a quality
control, 5% of the genotyped samples had their genotypes confirmed
by Sanger sequencing.
Statistical analysis
Quality control and case–control association analyses for both
Veracode and Kaspar assays were performed using PLINK
software, version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/)
(Purcell et al. 2007). SNPs with a low genotyping rate (<95%),
not fulfilling the Hardy–Weinberg equilibrium (HWE: P < 0.05), or
with a minimum allele frequency below 5%, as well as samples with
a low genotyping rate (<95%), were excluded from the association
analyses. We tested for association for two phenotypes: smoking
behavior, and level of addiction based on the Fagerstro¨m score. For
this, we considered smoking behavior as a dichotomic phenotype
(smoker vs. non-smoker), and we used the total Fagerstro¨m score,
either as a quantitative or a nominal variable: minimally (<4),
moderately (4–6) and highly (7–10) dependent. All association tests
included sex and age as covariates, and they were corrected for
multiple testing based on the Bonferroni correction (35 markers:
P < 0.0014). Linkage disequilibrium (LD) between polymorphisms
and haplotype block structures were evaluated using Haploview
software (version 4.1). Regions of strong LD were defined according
to the confidence intervals algorithm (Gabriel et al. 2002). We studied
haplotypes present at a frequency of at least 5%, and estimated the
significance of the best result via a permutation procedure (2000
permutations). The SNPassoc R package was used for all analyses
(Gonzalez et al. 2007).
Assessment of SNP function
We used WGAviewer (Ge et al. 2008) and Pupasuite 3.1
(http://pupasuite.bioinfo.cipf.es/) to assess the possible functional
consequences of the SNPs associated with smoking behavior. The
GENEVAR tool of WGAviewer was used to evaluate the effects of
SNPs on gene expression, based on Hapmap genotype and expres-
sion data (Stranger et al. 2005, 2007). Pupasuite was used to predict
the pathogenicity of an SNP based on the disruption of potential
transcription factor binding sites, the creation or disruption of splice




Ten SNPs (4 with a low genotyping rate, 1 not fulfilling HWE
and 5 with a low MAF) and 20 samples (with a low genotyping
rate) did not fulfill the aforementioned quality control criteria
and, thus, a total of 38 SNPs were analyzed in 153 cases
(TAB_Discovery) and 583 controls (CVH1) (Fig. 1 and Table 2).
No Mendelian errors were detected in the HapMap trios,
and 100% concordance was observed with the described
genotype in all cases. Allelic and genotypic (log-additive
model) association tests showed that three SNPs were
significantly associated with a lower risk of being a smoker
after Bonferroni correction for multiple testing [rs1424850
[P = 0.0002, odds ratio (OR) = 0.55, 95% confidence interval
(CI) = 0.40–0.76], rs221497 (P = 0.0020, OR = 0.47, 95%
CI = 0.28–0.79) and rs221473 (P = 0.0009, OR = 0.54, 95%
CI = 0.37–0.79); Table 3]. Based on the LD pattern of the
region, nine haplotype blocks were defined, and haplotype
association analysis showed an association of block 3 with
a decreased risk of being a smoker (OR = 0.44, 95% CI =
0.26–0.75; permuted P = 0.0025). This block spanned 16 kb
and included two of the SNPs identified in the single-SNP
analysis (rs221497 and rs221473; Table 4 and Fig. 2). We
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Table 3: Summary of the Veracode assay results: SNPs with a statistically significant association
TAB_Discovery vs. CVH1 TAB_Replication vs. CVH2 All
P value* OR (95% CI) P value* OR (95% CI) P value* OR (95% CI)
rs1424850 0.0002
†
0.55 (0.40–0.76) 0.59 0.94 (0.73–1.19) 0.0045 0.76 (0.73–0.92)





0.54 (0.37–0.79) 0.039 0.75 (0.57–0.99) 0.0003
†
0.67 (0.54–0.84)
∗Genotypic association under the log-additive model corrected by sex and age.
†Significant after Bonferroni correction for multiple testing.
Figure 1: SNPs location. Location of the 38 SNPs (including the CNV assay) along the α and β NRXN3 genomic region. SNPs
exhibiting association with nicotine addiction appear in bold.
also tested for any association with the level of addiction, as
determined by the Fagerstro¨m index, although no significant
relationships were observed for any of the SNPs evaluated.
Association analysis for NRXN3_del was performed
separately from the SNP analysis. After quality control, 154
cases and 580 controls were included in the analysis, and this
deleted allele was observed at a similar frequency in both the
cases and controls (cases: 0.42; controls: 0.40). Hence, there
was no association between the CNV polymorphism and
smoking behavior (P = 0.3, genotypic association; P = 0.46,
allelic association Fisher test).
Replication
To replicate these findings, the 3 SNPs exhibiting an associa-
tion were genotyped in an independent cohort of 276 individ-
uals addicted to nicotine (TAB_replication) and in an indepen-
dent control set (CVH2). We found a nominal association for
rs221473 (P = 0.039, OR = 0.75, 95% CI = 0.57–0.99) and
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Table 4: Haplotype association
TAB_Discovery vs. CVH1 TAB_Replication vs. CVH2 All
P value* OR (95% CI) P value* OR (95% CI) P value* OR (95% CI)
Haplotype
†
0.0031 0.46 (0.27–0.77) 0.037 0.68 (0.47–0.98) 0.0003 0.57 (0.42–0.77)
Permuted haplotype
‡
0.017 – 0.23 – 0.0075 –
∗Genotypic association under the log-additive model corrected by sex and age.
†rs221497(A)-rs221473(T): freq 0.11.
‡global P value for 2000 permutations.
rs221497 (P = 0.047, OR = 0.70, 95% CI = 0.49–1.00), and
their composite haplotype. When considering both cohorts,
the level of significance increased and haplotype association
persisted after permutation (OR = 0.57; 95% CI = 0.42–0.77,
permuted P = 0.0075; Tables 3 and 4).
Evaluation of SNP function
The three SNPs significantly associated with smoking
behavior were located in an intronic region, and in silico
evaluation of their functional implications using Genevar
showed no correlation between the SNP genotypes and
levels of expression. Evaluation of possible functional effects
using Pupasuite 3.1 showed that rs221497 and rs221449
were highly conserved as compared with the mouse
genome, although no potential functional consequences
were showed.
Discussion
In the present study, we performed a high-density SNP
association study of the link between NRXN3 and smoking
behavior in two independent samples of Spanish smokers.
Our findings show a significant association between two
NRXN3 SNPs and smoking behavior, and a nominal
association for a third SNP. To the best of our knowledge, this
is the first study to assess genetic variation in the NRXN3
gene by analyzing tagSNPs, additional putative functional
variants and structural variation.
NRXN3 is one of the three members of the neurexin gene
family. Neurexins are presynaptic cell adhesion proteins that
are essential for the development and function of synapses,
and that are implicated in neurotransmitter release. NRXN3 is
located on chromosome 14 and the two existing promoters
drive the expression of its α and β isoforms. Together with
five canonical sites of alternative splicing, these promoters
give rise to over 1000 isoforms (Rowen et al. 2002; Tabuchi
& Sudhof 2002). NRXN3 is expressed in key circuits
that have been implicated in addictive behaviors, including
glutamatergic neurons projecting from the prefrontal cortex
to the striatum and GABAergic neurons (Lein et al. 2007;
Ullrich et al. 1995). Hence, NRXN3 is a strong candidate for
substance abuse susceptibility.
Genetic variants in NRXN3 have been associated with
various substance dependence phenotypes (Bierut 2007;
Hishimoto 2007; Liu 2005; Novak 2009; Stoltenberg 2011),
including the degree of smoking in schizophrenic patients
(Novak et al. 2009) and nicotine dependence (Bierut et al.
2007). The convergence of associations between NRXN3 and
different phenotypes suggests that genetic factors contribute
to developing dependence on various classes of drugs
(Bierut 2011). Nevertheless, there is only a partial overlap
in the SNPs analyzed in each of the studies, various SNPs
have been analyzed in only one study, and the phenotypes
tested in the different studies, although related, are not the
same. It is possible that different SNPs in the same gene
are associated with the different substance dependence
phenotypes. Several of the SNPs included in this work have
also been analyzed in other studies (Table 2), although most
of them did not show any association. rs1004212 had been
associated with heavy smoking in schizophrenic patients and
has shown nominal association with alcohol problems in men
(Stoltenberg 2011), and rs8019381 had been associated with
alcohol dependence (Hishimoto 2007). However, we did not
find these SNPs associated with smoking behavior. Several
explanations can be offered for the conflicting SNPs identified
in different studies (including ours). First, as mentioned
above, although related, the phenotypes investigated in the
different studies are not the same, thus allowing for different
SNP associations. Also, previous studies were performed
on American (Bierut et al. 2007; Stoltenberg et al. 2011),
Canadian (Novak et al. 2009) and Australian (Bierut et al.
2007) populations, indicating that the failure to replicate
these data may also be due to genetic heterogeneity among
populations. Alternatively, the observed differences may
reflect distinct gene × environment interactions (Ioannidis
et al. 2007). Finally, it is possible that an untyped causative
variant in LD with the different signals identified in the NRXN3
gene may exist.
Population admixture in our sample may represent a
potential limitation to our analysis, although no significant
population effects have been observed in previous studies
on Spanish populations (Julia et al. 2008; Ribases et al.
2009). Moreover, all samples in the present study were
recruited in the same geographical region (Catalonia) and,
thus, the west-to-east trend reported previously is unlikely
to influence our data (Julia et al. 2008). Indeed, population
admixture was excluded from part of the control cohort in
an independent study (Ribases et al. 2009) and, hence, the
influence of population admixture in the present work is
probably negligible.
In our two-step study, the association observed was evi-
dent in both the discovery and replication cohorts, although
708 Genes, Brain and Behavior (2012) 11: 704–711
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the level of significance was lower in the latter of the two
cohorts. This is most probably due to clinical heterogeneity
between these patient cohorts, as the Fagerstro¨m index and
the number of cigarettes smoked per day were significantly
higher in the discovery cohort. Nonetheless, global analysis
of both cohorts together showed a significant protective
pooled effect.
Although we detected an association with status as a
smoker, we observed no association with the Fagerstro¨m
index (Table S1), suggesting that although related, these two
phenotypes may have distinct genetic bases. Alternatively,
a lack of statistical power may explain the failure to detect
association with the Fagerstro¨m index, given the smaller
effective sample size once the sample is divided into the
different Fagerstro¨m categories. In fact, we did observe an
association in two separate smoker cohorts, albeit in small
sample sets. Performing the replication study in a larger
cohort from a different population would provide strong
support for the present findings, and may even show an
association with the different categories defined by the
Fagerstro¨m index.
The two NRXN3 SNPs associated with smoking behavior
are located in an intronic region and no specific effect
was predicted for either SNP. Although this intronic region
is highly conserved between species, suggesting that it
fulfills an important role, it is possible that the SNPs
identified merely tag an as-yet-unidentified functional variant.
Next-generation sequencing technologies may help identify
additional functional variants within the gene that could have
been tagged by the associated SNPs. Targeted sequencing
of NRXN3 in larger nicotine addiction cohorts will be an
important next step to determine its role in substance
abuse. To better understand the functional involvement of
these and other SNPs in NRXN3, it will be of interest to
correlate these variants with the expression of different
splice variants. Other functional assays, such as testing the
response to nicotine exposure of neuronal cell lines carrying
the different genotypes, will also help elucidate the functional
consequences of these polymorphisms.
Despite finding no association between the NRXN3_del
variant and being a smoker, we have confidently identified
an INDEL by genotyping an internal SNP in combination
with a specifically designed assay. The concordance of
this genotyping technique with more traditional multiplex
PCR was 100%, suggesting that it constitutes a useful
tool to genotype common CNVs with known and defined
breakpoints in a high-throughput manner.
In summary, we describe new NRXN3 SNPs that
are associated with susceptibility to being a smoker in
agreement with previous studies implicating neurexins in
the development of addiction.
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